首页> 美国卫生研究院文献>other >The design and rationale of a multi-center clinical trial comparing twostrategies for control of systolic blood pressure: The Systolic Blood PressureIntervention Trial (SPRINT)
【2h】

The design and rationale of a multi-center clinical trial comparing twostrategies for control of systolic blood pressure: The Systolic Blood PressureIntervention Trial (SPRINT)

机译:多中心临床试验的设计和基本原理将两者进行比较控制收缩压的策略:收缩压干预试验(SPRINT)

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundHigh blood pressure is an important public health concern because it is highly prevalent and a risk factor for adverse health outcomes, including coronary heart disease, stroke, decompensated heart failure, chronic kidney disease, and decline in cognitive function. Observational studies show a progressive increase in risk associated with blood pressure above 115/75 mm Hg. Prior research has shown that reducing elevated systolic blood pressure lowers the risk of subsequent clinical complications from cardiovascular disease. However, the optimal systolic blood pressure to reduce blood pressure-related adverse outcomes is unclear, and the benefit of treating to a level of systolic blood pressure well below 140 mm Hg has not been proven in a large, definitive clinical trial.
机译:背景高血压是引起公众健康的重要问题,因为它非常普遍,并且是不良健康后果的风险因素,包括冠心病,中风,失代偿性心力衰竭,慢性肾脏疾病和认知功能下降。观察性研究表明,与高于115/75 mm Hg的血压相关的风险逐渐增加。先前的研究表明,降低收缩压升高会降低心血管疾病引起的后续临床并发症的风险。然而,降低收缩压相关不良后果的最佳收缩压尚不清楚,并且在大型的确定性临床试验中尚未证实将收缩压降至140 mm Hg以下的益处。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号